X4 Pharmaceuticals Inc (XFOR) Q4 2024 Earnings Call Highlights: Strategic Restructuring and ...
Cash and Cash Equivalents: Ended 2024 with just under $103 million.
Net XOLREMDI Revenues: $1.4 million for Q4 2024; $2.6 million for the full year 2024.
R&D Expenditures: $21.7 million for Q4 2024; $81.6 million for the full year 2024.
SG&A Expenses: $15.1 million for Q4 2024; $61.5 million for the full year 2024.
Net Loss: $39.8 million for Q4 2024; $37.5 million for the full year 2024, reflecting a one-time sale of a priority review voucher for $105 million.
Strategic Restructuring Savings: Expected to decrease spending by $30 million to $35 million annually.
Warning! GuruFocus has detected 5 Warning Signs with XFOR.
Release Date: March 25, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
X4 Pharmaceuticals Inc (NASDAQ:XFOR) achieved US approval and launched its first product, XOLREMDI, for WHIM syndrome in 2024.
The company has established strong partnerships with Norgine and Taiba Rare to expand the global reach of mavorixafor.
X4 Pharmaceuticals Inc (NASDAQ:XFOR) completed a successful Phase 2 trial for mavorixafor in chronic neutropenia, showing promising results.
The company has implemented a strategic restructuring to reduce annual spending by $30-35 million, extending operational runway.
X4 Pharmaceuticals Inc (NASDAQ:XFOR) ended 2024 with $103 million in cash and cash equivalents, providing financial stability into 2026.
X4 Pharmaceuticals Inc (NASDAQ:XFOR) reported a net loss of $37.5 million for the full year 2024.
The company faces regulatory uncertainties and a lengthy approval process for mavorixafor in Europe, with potential approval not expected until 2026.
X4 Pharmaceuticals Inc (NASDAQ:XFOR) is still in the early stages of building demand and awareness for XOLREMDI, with no specific patient numbers disclosed.
The company has not provided formal sales guidance for 2025, creating uncertainty about future revenue growth.
X4 Pharmaceuticals Inc (NASDAQ:XFOR) faces challenges in the competitive landscape of rare diseases, requiring significant investment in education and awareness campaigns.
Q: Can you expand on the regulatory conversation regarding the ANC threshold change from below 1,500 to below 1,000? Was this discussed before the trial initiation, and is there a risk of needing to upsize the trial? A: Dr. Paula Ragan, CEO, explained that the FDA is interested in ensuring the trial's success by focusing on moderate to severe patients. This alignment with the FDA does not impact the trial's pace, as the requirement for at least two infections per year already narrowed the patient funnel. Dr. Christophe Arbet-Engels, CMO, added that both the FDA and EMA support the approach, focusing on infection benefits rather than ANC as a non-validated biomarker.
Q: With the tightening of eligibility criteria around baseline ANC, do you expect this to slow down enrollment? A: Dr. Christophe Arbet-Engels stated that they do not expect a slowdown in enrollment as mild patients were not anticipated to represent a substantial number. The history of infections already narrowed the patient pool, and the screening process is progressing as expected.
Q: Can you provide an update on inventory levels and any early discounting trends? A: Adam Mostafa, CFO, noted that the balance sheet reflects inventory levels, which are expected to be lumpy over time based on demand. Mark Baldry, CCO, added that there is no discounting with payers at this time, maintaining a tight distribution channel through their specialty pharmacy.
Q: How many patients are currently on XOLREMDI, and was there a price increase for 2025? A: Mark Baldry stated they are not disclosing patient numbers as demand is still building. They did implement a 7% price increase at the start of 2025, which is typical for the new year.
Q: What are the commercialization goals for XOLREMDI in 2025, and how is the patient engagement strategy evolving? A: Mark Baldry explained that the focus is on building awareness and education around WHIM syndrome. They are leveraging physician experience through a peer-to-peer speaker program and pivoting to engage the patient community. The goal is to increase demand by activating both physicians and patients, with payers quickly reimbursing the product.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
reAlpha Expands Homebuying Platform into Texas, Marking First Step in National Realty Rollout
DUBLIN, Ohio, June 13, 2025 (GLOBE NEWSWIRE) -- reAlpha Tech Corp. (Nasdaq: AIRE) ('reAlpha' or the 'Company'), an AI-powered real estate technology company, today announced the expansion of its platform into Texas1 with the launch of real estate brokerage services through its REALTOR® affiliate. This milestone marks the first step in bringing reAlpha's end-to-end homebuying experience to states outside of Florida, starting with one of the most active real estate markets in the country. Texas is the second‑most populous state2 in the U.S. and recorded over 323,000 home sales in 2024, with a median sale price of $347,000, representing more than $112 billion in residential transaction value3. This expansion into Texas positions reAlpha to reach millions of prospective homebuyers through a tech-enabled, streamlined platform that delivers real savings at closing, including in high-volume markets such as Dallas-Fort Worth, San Antonio, Houston, and Austin. 'This is an exciting next step in reAlpha's national expansion,' said Mike Logozzo, Chief Executive Officer of reAlpha. 'Texas is a high-volume, high-potential market that aligns perfectly with our integrated business model. We aim to bring real value to homebuyers by combining technology-driven convenience with cost savings, and Texas is just the beginning.'reAlpha already has an established presence in Texas through its strategic acquisition of their licensed mortgage subsidiary, Be My Neighbor, which has been serving customers there since 2018 and currently operates across 30 states. With the addition of real estate brokerage capabilities in Texas, reAlpha is now delivering a more integrated experience on its end to end platform from search to preapproval to close. The Company plans to launch in additional states in the coming months as it scales its platform and continues executing its mission to modernize real estate through AI, data, and integrated experiences. About reAlpha Tech Tech Corp. (Nasdaq: AIRE) is an AI-powered real estate technology company transforming the multi-trillion-dollar U.S. real estate services market. reAlpha is developing an end-to-end platform that streamlines real estate transactions through integrated brokerage, mortgage, and title services. With a strategic, acquisition-driven growth model and proprietary AI infrastructure, reAlpha is building a vertically integrated ecosystem designed to deliver a simpler, smarter, and more affordable path to homeownership. For more information, visit Forward-Looking StatementsThe information in this press release includes 'forward-looking statements.' Any statements other than statements of historical fact contained herein, including statements by our Chief Executive Officer, Mike Logozzo, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as 'may', 'should', 'could', 'might', 'plan', 'possible', 'project', 'strive', 'budget', 'forecast', 'expect', 'intend', 'will', 'estimate', 'anticipate', 'believe', 'predict', 'potential' or 'continue', or the negatives of these terms or variations of them or similar terminology. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: reAlpha's ability to pay contractual obligations; reAlpha's liquidity, operating performance, cash flow and ability to secure adequate financing; reAlpha's limited operating history and that reAlpha has not yet fully developed its AI-based technologies; whether reAlpha's technology and products will be accepted and adopted by its customers and intended users; reAlpha's ability to commercialize its developing AI-based technologies; reAlpha's ability to successfully enter new geographic markets; reAlpha's ability to integrate the business of its acquired companies into its existing business and the anticipated demand for such acquired companies' services; reAlpha's ability to scale its operational capabilities to expand into additional geographic markets and nationally; the potential loss of key employees of reAlpha and of its subsidiaries; the outcome of certain outstanding legal proceedings against reAlpha; reAlpha's ability to obtain, and maintain, the required licenses to operate in the U.S. states in which it, or its subsidiaries, operate in, or intend to operate in; reAlpha's ability to successfully identify and acquire companies that are complementary to its business model; the inability to maintain and strengthen reAlpha's brand and reputation; any accidents or incidents involving cybersecurity breaches and incidents; the inability to accurately forecast demand for AI-based real estate-focused products; the inability to execute business objectives and growth strategies successfully or sustain reAlpha's growth; the inability of reAlpha's customers to pay for reAlpha's services; the inability of reAlpha to obtain additional financing or access the capital markets to fund its ongoing operations on acceptable terms and conditions; the outcome of any legal proceedings that might be instituted against reAlpha; changes in applicable laws or regulations, and the impact of the regulatory environment and complexities with compliance related to such environment; and other risks and uncertainties indicated in reAlpha's SEC filings. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements. Although reAlpha believes that the expectations reflected in the forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. reAlpha's future results, level of activity, performance or achievements may differ materially from those contemplated, expressed or implied by the forward-looking statements, and there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking statements. For more information about the factors that could cause such differences, please refer to reAlpha's filings with the SEC. Readers are cautioned not to put undue reliance on forward-looking statements, and reAlpha does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Media Contact:Cristol Rippe, Chief Marketing Officermedia@ Investor Relations Contact:Adele Carey, VP of Investor Relationsinvestorrelations@ 1 The reAlpha platform is currently available in 212 out of 254 counties in Texas2 in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
Micron Plots $200 Billion U.S. DRAM Buildout
Micron Technology (NASDAQ:MU) is boosting its U.S. memory-manufacturing and R&D investment to $200 billion, aiming to onshore 40 percent of its DRAM output. The plan calls for two new high-volume fabs in Idahoone slated to start DRAM production in 2027four more fabs in New York, and an expanded, modernized facility in Virginia, alongside advanced HBM packaging and research initiatives. To finance the buildout, Micron has locked in $275 million under the CHIPS and Science Act and is eligible for up to $6.4 billion in direct funding for its Idaho and New York sites. CEO Sanjay Mehrotra said the move underscores our commitment to driving innovation and strengthening the domestic semiconductor industry, while Commerce Secretary Gina Raimondo added the investment will ensure the U.S. advances its lead across critical industries like AI, automotive, and aerospace and defense. Amazon (NASDAQ:AMZN) Web Services chief Matt Garman praised the expansion as a significant milestone for the semiconductor industry. Even as shares dipped 0.21 percent on the news, analysts note that onshoring DRAM production could shorten supply chains, improve margin visibility and reduce geopolitical risk. Why It Matters: With global memory demand surgingespecially for AI applicationssecuring a domestic production base could give Micron a strategic edge and help the U.S. lessen dependence on overseas fabs. Additionally, Micron Technology has rebounded from earlier lows and now carries a 12-month price target of $121.82, suggesting a modest 5.26% upside. The projections vary widely, with a high-end forecast of $172 and a low of $60, signaling some uncertainty. After dipping below $70 earlier this year, the stock has climbed steadily and analysts seem cautiously optimistic moving forward. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
31 minutes ago
- Yahoo
Aptevo Participating in the BIO International Convention
SEATTLE, WA / / June 13, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced that the Company is participating in the BIO International Convention occurring June 16-19, 2025, in Boston, MA. The conference is known for being the largest biotechnology industry conference of the year and is expected to attract more than 18,000 attendees from around the world. Attending from Aptevo are Michelle N. Nelson, Ph.D., Director of Immunobiology and SoYoung Kwon, SVP, General Counsel and Head, Business Development. About Aptevo TherapeuticsAptevo Therapeutics Inc. (NASDAQ:APVO) is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates. Mipletamig is currently being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation ("orphan status") for AML according to the Orphan Drug Act. a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates were created from two proprietary platforms, ADAPTIR® and ADAPTIR-FLEX®. The Aptevo mission is to improve treatment outcomes and transform the lives of cancer patients. For more information, please visit Safe Harbor StatementThis press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, Aptevo's expectations about the activity, efficacy, safety, tolerability and durability of its therapeutic candidates and potential use of any such candidates, including in combination with other drugs, as therapeutics for treatment of disease, its expectations regarding the effectiveness of its ADAPTIR and ADAPTIR-FLEX platforms, statements related to the progress of Aptevo's clinical programs, including statements related to anticipated clinical and regulatory milestones, whether further study of mipletamig in a Phase 1b dose optimization trial focusing on multiple doses of mipletamig in combination with venetoclax + azacitidine on a targeted patient population will continue to show clinical benefit, whether Aptevo's final trial results will vary from its earlier assessment, the possibility and timing of interim data readouts for statements related to Aptevo's ability to generate stockholder value, whether Aptevo will continue to have momentum in its business in the future, and any other statements containing the words "may," "continue to," "believes," "knows," "expects," "optimism," "potential," "designed," "promising," "plans," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Aptevo's current intentions, beliefs, and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo's expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. There are several important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo's business or prospects; further assessment of preliminary or interim data or different results from later clinical trials; adverse events and unanticipated problems, adverse developments in clinical development, including unexpected safety issues observed during a clinical trial; and changes in regulatory, social, macroeconomic and political conditions. For instance, actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the uncertainties inherent in the results of preliminary or interim data and preclinical studies being predictive of the results of later-stage clinical trials, initiation, enrollment and maintenance of patients, and the completion of clinical trials, the availability and timing of data from ongoing clinical trials, the trial design includes combination therapies that may make it difficult to accurately ascertain the benefits of mipletamig, expectations for the timing and steps required in the regulatory review process, expectations for regulatory approvals, the impact of competitive products, our ability to enter into agreements with strategic partners or raise funds on acceptable terms or at all and other matters that could affect the availability or commercial potential of Aptevo's product candidates, business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises such as the coronavirus (referred to as COVID-19), geopolitical risks, including the current war between Russia and Ukraine and the war between Israel and Hamas, and macroeconomic conditions such as economic uncertainty, rising inflation and interest rates, continued market volatility and decreased consumer confidence. These risks are not exhaustive, Aptevo faces known and unknown risks. Additional risks and factors that may affect results are set forth in Aptevo's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and its subsequent reports on Form 10-Q and current reports on Form 8-K. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Aptevo's expectations in any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not assume any obligation to update any forward-looking statement to reflect new information, events, or circumstances. CONTACT:Miriam Weber MillerHead, Investor Relations & Corporate CommunicationsAptevo TherapeuticsEmail: IR@ or Millerm@ 206-859-6628 SOURCE: Aptevo Therapeutics View the original press release on ACCESS Newswire
